CN106563089A - Medicine for treating couperose skin and preparation method of medicine - Google Patents

Medicine for treating couperose skin and preparation method of medicine Download PDF

Info

Publication number
CN106563089A
CN106563089A CN201610990523.4A CN201610990523A CN106563089A CN 106563089 A CN106563089 A CN 106563089A CN 201610990523 A CN201610990523 A CN 201610990523A CN 106563089 A CN106563089 A CN 106563089A
Authority
CN
China
Prior art keywords
medicine
red blood
blood silk
preparation
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610990523.4A
Other languages
Chinese (zh)
Inventor
傅天锡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610990523.4A priority Critical patent/CN106563089A/en
Publication of CN106563089A publication Critical patent/CN106563089A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8967—Lilium, e.g. tiger lily or Easter lily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to the fields of medical science and pharmacology, and in particular relates to a medicine for treating couperose skin and a preparation method of the medicine. The medicine is an oral preparation prepared from the raw materials including echinacea purpurea, rhizoma fagopyri dibotryis, spina date seeds, roots of Gypsophila oldhamiana Miq., lily bulbs, flos gardeniae, fructus momordicae, cortex cercis chinensis, radix cynanchi atrati, herba artemisiae scopariae, rose flowers, herba diclipterae chinensis, herba galii, radix platycodi, the root bark of the peony tree, herba begoniae fimbristipulatae, folium hibisci mutabilis, radix notoginseng and the like by combining with the traditional Chinese medicine theory and the latest pharmacological research achievements and by adopting the modern technological means; the oral preparation is preferably capsules, tablets and granules. The pharmacodynamic experiment researches show that the medicine has the ideal treatment effect for couperose skin, and the medicine is convenient to use and good in safety; all the raw materials are natural medicinal plants or daily foods, no chemical additives are adopted, thus the medicine is safe and reliable for long-term administration, the tolerance and compliance of patients can be greatly improved, therefore, a novel selection scheme is provided for the long-term therapy of the patients suffering from couperose skin, and the clinical demands at present are satisfied.

Description

A kind of medicine and preparation method for treating red blood silk
Technical field
The present invention relates to medical science and field of pharmacology, more particularly to a kind of medicine and preparation method for treating red blood silk.
Background technology
Red blood silk is primarily due to facial cuticula weakness, cuticula and is damaged or a part of capillary also known as red blood trace on face Vessel position table is shallow to cause capillary easily to contact and sensing external environment change, so as to cause skin capillary vascular expansion And the facial phenomenon for causing, carefully the trace of blood is crisscross to show as redness, and such as cobweb, dispersiveness distribution, severe patient can be linked to be Sheet.Patient facial region looks redder compared with normal skin tone, i.e., people often claim plateau face or egg of blushing, and some patients are only two Side cheekbone portion is rubescent, and border is rounded, more in silk the linear alignment.This skin is thin and sensitive, supercooling, overheated, excited, temperature Face is redder during suddenly change, and severe patient can also form deposition color spot, it is difficult to cure.
The cause of disease of red blood silk is complex, and its basic reason is that cutaneous immunisation is lowly caused.It is commonly referred to be due to face Cuticula is damaged, and capillary loses cuticular natural protection, so as to be stimulated by external environment for a long time, ultimately results in blood It is enlargement of pipe, silting, impaired and formed.Specifically, the reason for causing red blood trace on face is varied, main to include making for a long time With the medicines such as tartaric acid, external force extruding, acarid is parasitic, flame fire-cures, plateau climate stimulates, frostbite, disease factor, ultraviolet spoke Penetrate, Long-Time Service corticoid medicine, hobby tobacco and wine, poor eating habits, skin sensitivity etc..It is further preferred that With the development of modern beauty industry, improperly aesthetic nursing also becomes the important origin cause of formation of red blood silk, such as in skin care item it is acid into Part damage and hormonal dependent telangiectasis rupture, and to change the cutaneous immunisation power that skin causes low, is contained using some The cosmetics of heavy metal cause toxin to remain epidermis, destroy cuticula, cause sensitivity response；Additionally, face nursing is inhaled in beauty also can Telangiectasis is caused to rupture, cuticula polishing, photon delicate skin etc. also result in cuticula and suffer damage and cause red blood silk.
Although red blood silk will not bring violent uncomfortable to patient, it can badly influence the appearance shape of patient As, and then cause huge shade to patients ' psychological, if symptom cannot be controlled for a long time or improved, or even can cause anxiety, The generation of the mental illnesses such as depression.
At present, the treatment for red blood silk mainly improves the elasticity of facial capillary, recovers the normal contraction of blood vessel With diastolic function, vasopermeability is reduced.Treatment method includes living cells therapy, physical treatment, drug therapy, Chinese traditional treatment Deng, wherein living cells therapy is exactly to provide the cell that bio signal repairs skin epidermis using the albumen of strong biological activity, and Nutrition is provided to epidermal layer cells, fine and close cuticula defense system is rebuild, so as to reaching treatment or improving the effect of red blood silk Really, this method therapeutic effect is preferable, but it is sufficiently expensive to treat price；Physical therapy modalities are then using the laser of specific wavelength Skin is irradiated and the effect for dispelling red blood silk is reached, but on the one hand laser irradiation operates inconvenience, another aspect security Hidden danger is there is also, secondary injury is easily caused；Drug therapy mainly includes some corticosteroid hormone paste, although can be short Rapid relief of symptoms in time, but this kind of medicine bad reaction is more, is also easy to produce dependence, and symptom is by recurrent exerbation, skin after drug withdrawal Skin is more sensitive；Chinese traditional treatment typically constitutes compound using blood-activating stasis-removing kind Chinese medicine, and be prepared into the form of externally used paste is used for more Smear affected part, although can relief of symptoms, but be difficult fundamentally to correct the cause of disease, therefore curative effect and imprecise, use in addition There is inconvenience come also more.
To sum up, because the various treatment methods currently for red blood silk all have significant limitation in implementation process, Therefore, considerable patient still effectively treats.In consideration of it, be clinically badly in need of a kind of determined curative effect, it is easy to use, Security is good, bad reaction is few and the relatively low novel drugs for the treatment of cost.The present invention is in extensive retrieval, Large-scale Screening, repetition A kind of novel drugs for treating red blood silk are obtained on the basis of checking.Jing is tested, and medicine of the present invention has preferable to red blood silk Therapeutic action, and easy to control the quality, determined curative effect of the invention, convenient use, high safety and treatment cost is relatively low；Medicine of the present invention The all raw materials of thing are all from natural medicinal plant or conventional food, without any chemical addition agent, take safe and reliable；This It is bright to be easy to carry and take for peroral dosage form, easily it is easily accepted by the patient.Therefore, medicine of the present invention is especially suitable for current clinic Demand, the popularization and application of the present invention will have good market prospects and produce considerable economic and social benefit.
The content of the invention
The technical problem of solution
The present invention need solve problem be：Because the various treatment methods currently for red blood silk all have in implementation process There is significant limitation, such as living cells therapy is expensive；Laser therapy operation is inconvenient, easily cause secondary injury；Western medicine is not Good reaction is more, be also easy to produce dependence and withdrawal reaction, patient tolerability and compliance are poor；Compound Chinese medicinal preparation uses inconvenience, hardly possible Fundamentally correct the cause of disease, uncertain therapeutic efficacy to cut, the problems referred to above that existing medicine is present cause considerable red blood silk patient to obtain Less than effectively treatment.
Technical scheme
The present invention is intended to provide a kind of determined curative effect for treating red blood silk, property easy to use, safe be good, bad reaction is few and And the relatively low novel drugs for the treatment of cost and preparation method thereof.
The medicine of the treatment red blood silk of the present invention, it is characterised in that it is by made by the raw material of following weight proportioning：
The weight proportion of above-mentioned raw materials is preferred：
The weight proportion of above-mentioned raw materials is further preferably：
The weight proportion of above-mentioned raw materials is further preferably：
The medicine of present invention treatment red blood silk can be any conventional pharmaceutical dosage form, preferred capsule, tablet, particle Agent.
The medicine capsule of present invention treatment red blood silk can be prepared by the following method and form：
1) by Echinacea purpurea, cymose buckwheat rhizome, spina date seed, rosy clouds grass, lily, gardenia, Momordica grosvenori, Kadsura Root-bark, radix cynanchi atrati, oriental wormwood, rose Rare flower, Dicliptera chinensis, catchweed bedstraw herb, balloonflower root, the root bark of tree peony, fimbriatestipulate begonia herb, cogongrass rhizome, climbing groundsel, frankincense, Poria cocos, globe amaranth, sanchi flower, ice 8-12 times is added to measure water, immersion 1 after sugar grass, Ligusticum wallichii, Radix Glycyrrhizae, amaranth and the mixing of FOLIUM HIBISCI MUTABILIS medicinal material, water rinsing, dry, crushing After hour, 1-3 hours are decocted, liquid filtration, filtrate is standby, repeat the dregs of a decoction to decoct 2-3 time under the same conditions, merge filter Liquid, is evaporated to after small size and obtains mixing medicinal substances extract concentrate, sprays to mixing medicinal substances extract concentrate It is dried, obtains spray dried powder standby；
2) to take and carry out meal after the rinsing of pseudo-ginseng water, drying, the coarse powder particles of gained are put into into micronizer is carried out Ultramicro grinding, gained ultra-micro powder crosses that to obtain superfine notoginseng powder after 100-500 mesh sieves standby；
3) spray dried powder obtained in above steps and superfine notoginseng powder are mixed, is fully mixed in mixer, made 8-20 mesh sieves are crossed after grain, is dried, with 8-20 mesh sieve whole grains, capsule is filled after sterilization, packed, obtain final product this medicine capsule.
Further, the preparation method of medicinal tablet of the present invention and granule is：Step with it is above-mentioned 1), 2) step, the 3) step Carry out by the conventional method for preparing tablet and granule in this area, this medicinal tablet and granule is obtained.
Beneficial effect
The present invention is obtained on the basis of extensive retrieval, Large-scale Screening, repeated authentication and a kind of treats the new of red blood silk Medicine.Jing is tested, and medicine of the present invention has preferable therapeutic action to red blood silk, and easy to control the quality, determined curative effect of the invention, is made With convenience, security is good, bad reaction is few and treatment cost is relatively low；The all raw materials of medicine of the present invention are all from natural medicinal plant Or conventional food, without any chemical addition agent, take safe and reliable；The present invention is peroral dosage form, is easy to carry and takes, Easily it is easily accepted by the patient.Therefore, medicine of the present invention is especially suitable for current clinical demand, and the popularization and application of the present invention will have Good market prospects simultaneously produce considerable economic and social benefit.
Specific embodiment
Embodiments of the present invention are illustrated below by way of specific instantiation, those skilled in the art can be by this specification Disclosed content understands easily other advantages and effect of the present invention.The present invention can also pass through concrete realities different in addition The mode of applying is carried out or applies, the every details in this specification can also based on different viewpoints with application, without departing from Various modifications and changes are carried out under the spirit of the present invention.
Before the specific embodiment of the invention is further described, it should be appreciated that protection scope of the present invention is not limited to down State specific specific embodiment；It is also understood that the term used in the embodiment of the present invention is specific concrete in order to describe Embodiment, rather than in order to limit the scope of the invention；In description of the invention and claims, unless in text Explicitly point out in addition, singulative " one ", " one " and " this " include plural form.
When embodiment provides number range, it should be appreciated that except non-invention is otherwise noted, two ends of each number range Any one numerical value can select between point and two end points.Unless otherwise defined, the present invention used in all technologies and Scientific terminology is identical with the meaning that those skilled in the art of the present technique are generally understood that.Except the concrete grammar used in embodiment, equipment, Outside material, according to those skilled in the art to the grasp of prior art and the record of the present invention, can also use and this Any method of the similar or equivalent prior art of method, equipment described in inventive embodiments, material, equipment and material come real The existing present invention.
Embodiment 1
A kind of medicine for treating red blood silk, this medicine is by made by the raw material of following weight proportioning：
Preparation method is as follows：
1) by Echinacea purpurea, cymose buckwheat rhizome, spina date seed, rosy clouds grass, lily, gardenia, Momordica grosvenori, Kadsura Root-bark, radix cynanchi atrati, oriental wormwood, rose Rare flower, Dicliptera chinensis, catchweed bedstraw herb, balloonflower root, the root bark of tree peony, fimbriatestipulate begonia herb, cogongrass rhizome, climbing groundsel, frankincense, Poria cocos, globe amaranth, sanchi flower, ice Add 8 times of amount water after sugar grass, Ligusticum wallichii, Radix Glycyrrhizae, amaranth and the mixing of FOLIUM HIBISCI MUTABILIS medicinal material, water rinsing, dry, crushing, soak 1 hour Afterwards, decoct 2 hours, liquid filtration, filtrate is standby, repeat the dregs of a decoction to decoct 3 times under the same conditions, merging filtrate reduces pressure dense It is reduced to after small size and obtains mixing medicinal substances extract concentrate, be spray-dried to mixing medicinal substances extract concentrate, must sprays Mist xeraphium is standby；
2) to take and carry out meal after the rinsing of pseudo-ginseng water, drying, the coarse powder particles of gained are put into into micronizer is carried out Ultramicro grinding, gained ultra-micro powder crosses that to obtain superfine notoginseng powder after 100 mesh sieves standby；
3) spray dried powder obtained in above steps and superfine notoginseng powder are mixed, is fully mixed in mixer, made 12 mesh sieves are crossed after grain, is dried, with 14 mesh sieve whole grains, capsule is filled after sterilization, packed, obtain final product this medicine capsule.
Embodiment 2
A kind of medicine for treating red blood silk, this medicine is by made by the raw material of following weight proportioning：
Preparation method is as follows：
1) by Echinacea purpurea, cymose buckwheat rhizome, spina date seed, rosy clouds grass, lily, gardenia, Momordica grosvenori, Kadsura Root-bark, radix cynanchi atrati, oriental wormwood, rose Rare flower, Dicliptera chinensis, catchweed bedstraw herb, balloonflower root, the root bark of tree peony, fimbriatestipulate begonia herb, cogongrass rhizome, climbing groundsel, frankincense, Poria cocos, globe amaranth, sanchi flower, ice Add 10 times of amount water after sugar grass, Ligusticum wallichii, Radix Glycyrrhizae, amaranth and the mixing of FOLIUM HIBISCI MUTABILIS medicinal material, water rinsing, dry, crushing, immersion 1 is little Shi Hou, decocts 3 hours, and liquid filtration, filtrate is standby, repeats the dregs of a decoction to decoct 2 times under the same conditions, merging filtrate, decompression It is concentrated into after small size and obtains mixing medicinal substances extract concentrate, be spray-dried to mixing medicinal substances extract concentrate, obtains Spray dried powder is standby；
2) to take and carry out meal after the rinsing of pseudo-ginseng water, drying, the coarse powder particles of gained are put into into micronizer is carried out Ultramicro grinding, gained ultra-micro powder crosses that to obtain superfine notoginseng powder after 300 mesh sieves standby；
3) spray dried powder obtained in above steps and superfine notoginseng powder are mixed, is fully mixed in mixer, so Afterwards this medicinal tablet is obtained by the conventional method for preparing tablet thereof in this area.
Embodiment 3
A kind of medicine for treating red blood silk, this medicine is by made by the raw material of following weight proportioning：
Preparation method is as follows：
1) by Echinacea purpurea, cymose buckwheat rhizome, spina date seed, rosy clouds grass, lily, gardenia, Momordica grosvenori, Kadsura Root-bark, radix cynanchi atrati, oriental wormwood, rose Rare flower, Dicliptera chinensis, catchweed bedstraw herb, balloonflower root, the root bark of tree peony, fimbriatestipulate begonia herb, cogongrass rhizome, climbing groundsel, frankincense, Poria cocos, globe amaranth, sanchi flower, ice Add 12 times of amount water after sugar grass, Ligusticum wallichii, Radix Glycyrrhizae, amaranth and the mixing of FOLIUM HIBISCI MUTABILIS medicinal material, water rinsing, dry, crushing, immersion 1 is little Shi Hou, decocts 1 hour, and liquid filtration, filtrate is standby, repeats the dregs of a decoction to decoct 2 times under the same conditions, merging filtrate, decompression It is concentrated into after small size and obtains mixing medicinal substances extract concentrate, be spray-dried to mixing medicinal substances extract concentrate, obtains Spray dried powder is standby；
2) to take and carry out meal after the rinsing of pseudo-ginseng water, drying, the coarse powder particles of gained are put into into micronizer is carried out Ultramicro grinding, gained ultra-micro powder crosses that to obtain superfine notoginseng powder after 500 mesh sieves standby；
3) spray dried powder obtained in above steps and superfine notoginseng powder are mixed, is fully mixed in mixer, so Afterwards this medicinal granule is obtained according to the conventional process for producing granula in this area.
Pharmacodynamic information
This test objective is the treatment for observing and verifying Chinese medicine composition of the present invention (medicine in embodiment 2) to red blood silk Effect.
This test agents useful for same is as follows：
1. test medicine：Chinese medicine composition；Unit is provided：Self-control；Proterties and physicochemical property：Dark brown granule.
2. control drug：Chinese medicine composition (do not contain Echinacea purpurea in formula, remaining raw medicinal material species and proportioning all with it is tested Medicine is identical)；Unit is provided：Self-control；Proterties and physicochemical property：Dark brown granule.
3. positive drug：Loratadine；Production unit：Nanjing sage and medicine company limited company, lot number：A154217.
4. modeling agent：Fluorescein-5-isothiocyanate；Production unit：Shang Hai Tuo Yang bio tech ltd.
5. sterilized water for injection, production unit：Qidu Pharmaceutical Co., Ltd., Shandong Prov., lot number：2A14150503.
Animal used as test：
Animal species：BALB/c mouse inbred lines
Animal Sex：Female
Animal level：Cleaning grade
The weight of animals：18～22g；The weight of animals is between the 80%～120% of the sex animal average weight.
Number of animals：50
Animal used as test is originated：Beijing Vital River Experimental Animals Technology Co., Ltd.；Animal used as test production licence number： SCXK (capital) 2012-0001；The Quality of Experimental Animals quality certification is numbered：11400700103783；Production licence signs and issues unit：North Science and Technology Commission of capital city.
The reasons why animal used as test selects：This test is from the mark that BALB/c mouse inbred lines is used in medicine non-clinical study Quasi- animal, with substantial amounts of background data, genetic background understands, the reaction to medicine is more stable, and individual difference is less, raises Convenient, the bodily form is less, is easy to test operation, saves test sample, and is the discovery that when same or like test sample is studied properly Animal model.
Test sample is prepared：
Preparation time and frequency：The administration same day carries out the preparation of test sample, and solvent is prepared 1 time for 1 week.
Test medicine compound method：Chinese medicine composition is configured to into suspension of the concentration as 25.0mg/ml with water.
Control drug compound method：Chinese medicine composition (without Echinacea purpurea in formula) is configured to into concentration as 25.0mg/ with water The suspension of ml.
Positive drug compound method：Loratadine is configured to into suspension of the concentration as 0.125mg/ml with water.
Modeling method：
50 mouse fasting 12 hours, then every mouse web portion is picked apply after hair 0.5% Fluorescein-5-isothiocyanate (solvent is acetone：Dibutyl phthalate=1:1) 400ul sensitization, applies 0.5% fluorescein -5- on the 5th day different in mouse right ear Rhodanate 20ul is excited, and left ear applies corresponding solvent (acetone/dibutyl phthalate) as negative control, before exciting and Rear 24h feelers are excited to measure left and right ear thickness, feeler distal end is mutually pressed close to ensure measurement every time with mouse helix inner edge Position it is consistent, △ T=excite rear 24h ears thickness-excite vestibule thickness, ear swelling degree to change with (△ T ± standard deviations) table Show.As a result show：Excite the visible 48 mouse right ear rednesses of rear 24h naked eyes, thicken substantially, Jing measurements, model auris dextra swelling Significantly thicken with the true epidermal thickness of ear ear left than negative control, illustrate this dermatitis model modeling success.
Test packet：
From 40 mouse that selective body heavy phase in the successful mouse of 48 modelings is near, 4 groups, i.e. positive controls are randomly divided into (with Loratadine suspension oral gavage), test sample group (with Chinese medicine composition suspension oral gavage), comparison medicine group (with formula without pine The Chinese medicine composition suspension oral gavage of fruit chrysanthemum), blank control group (with water for injection gavage).
Medication：
Method of administration：Oral administration gavage is administered.
Dosage rate and cycle：It is administered once daily, successive administration 14 days.
Administering mode and dosage：Test sample group：250mg/kg body weight, is administered by 0.1ml/10g body weight, and daily morning weighs After body weight, test sample suspension is given.Positive drug group：1.25mg/kg body weight, is administered by 0.1ml/10g body weight, and daily morning claims After weighing sb., Loratadine suspension is given.Comparison medicine group administering mode is identical with test sample group.Blank control group：It is daily early After morning weighs in, by 0.1ml/10g body weight water for injection is given.
Living animal Testing index：
General clinical observation：Including but not limited to death condition, the state of mind, behavioral activity, morbidity, breathing, secretion, Excrement and diet and drinking-water situation etc..
Detailed clinical is observed：Including but not limited to the state of mind, behavioral activity, skin, by hair, eyes, ear, nose, abdomen Portion, external genital organs, anus, four limbs, foot and breathing.
Body weight：All animals determine body weight with before packet after the receipt, and determine body weight before the dying euthanasia of animal.
Ear swelling degree is detected：
Detection time：24h, D4, D7, D14 before modeling, before first administration and after first administration.
Detection method：Feeler is determined.
Determine numerical value：Determine every time repeatedly to survey three times and average.
Result of the test：Test sample group, positive drug group and comparison medicine group show significant anti-inflammatory antiallergic effect, experimental period Between, the change of each group animal ear swelling degree is mainly shown as after administration that 24h is substantially unchanged, D4, D7 test sample group, positive drug group It is obviously improved with comparison medicine group ear thickness, and blank control group D7 also has some improvement, D14 test sample group ear swellings Situation is wholly absent, and positive drug group and comparison medicine group still have slight ear swelling, and blank control group ear swelling situation has been delayed Solution.
Ear swelling degree table before and after each test group animal administration of table 1
Note：Ear swelling degree shown in table：Auris dextra thickness/left ear thickness × 100%, n=10；
" * " is represented and P≤0.05 compared with organizing before administration；
" * * " is represented and P≤0.01 compared with organizing before administration；
" * * * " is represented and P≤0.001 compared with organizing before administration.
From in terms of ear swelling degree result before and after the administration of each test group animal, compared with administration vestibule swelling, after first administration 24h each group animal ear swelling degree is substantially unchanged, and D4, D7 test sample group, positive drug group and comparison medicine group ear thickness are bright It is aobvious to improve, and blank control group D7 also has some improvement, D14 test sample group ear swelling situations are wholly absent, positive drug group Still there is slight ear swelling with comparison medicine group, blank control group ear swelling situation has been alleviated.
Conclusion (of pressure testing)：
Test sample group, positive drug group and comparison medicine group are respectively provided with significant anti-inflammatory antiallergic effect, are mainly manifested in：Respectively with , to mouse stomach, successive administration 14 days, each group just shows after being administered 4 days for Chinese medicine composition, positive drug, control drug Certain anti-inflammatory antiallergic effect, when administration 7 days, test sample group mice ear situation is substantially eliminated, comparison medicine group and sun Property medicine group mice ear degree also have clear improvement, treat 14 days administration at the end of, test sample group ear swelling situation is wholly absent, Positive drug group and comparison medicine group still have slight ear swelling, and blank control group ear swelling situation has been alleviated, before each group administration Ear swelling degree is compared, and test sample group and positive drug group are respectively provided with pole significant difference (P≤0.001), and comparison medicine group has more significant Difference (P≤0.01), blank control group has difference (P≤0.05), illustrates that this inflammatory reaction has certain self-healing property.Administration When 14 days, this Chinese medicine composition compared with positive drug Loratadine, the effect of its anti-inflammatory antiallergic also have significant difference (P≤ 0.05), illustrate the long-term anti-inflammatory antiallergic effect of this Chinese medicine composition better than positive drug Loratadine.When being administered 14 days, this Chinese medicine Compared with the comparison medicine without Echinacea purpurea in formula, its anti-inflammatory antiallergic effect also has significant difference (P≤0.05) to composition, The long-term anti-inflammatory antiallergic effect for illustrating this Chinese medicine composition is substantially better than comparison medicine, while also illustrating Echinacea purpurea in this Chinese traditional medicine composition Important and prominent effect is served in thing, the synergy just because of Echinacea purpurea and other various raw medicinal materials is caused in this Drug composition is provided with preferably long-term anti-inflammatory antiallergic effect.
Clinical testing
This test objective is the therapeutic effect for observing and verifying medicine of the present invention (medicine in embodiment 2) to red blood silk.
First, case selection and packet
All 30, it is randomly divided into treatment group and control group, per group each 15.
Two groups of ages, sex, the course of disease, clinical manifestation and the not statistically significant (p of coincident with severity degree of condition comparing difference> 0.05)。
2nd, diagnosis basis and inclusive criteria
(1) age requirement 18-65 one full year of life；
(2) red blood silk clinical criteria is met；
(3) test in first 1 week and do not take other treatment medicine；
(4) without other serious organ diseases；
(5) agree to participate in this test, and signed Informed Consent Form.
3rd, exclusion standard
(1) age is below 18 one full year of life or 65 one full year of life above persons；
(2) gestational period or women breast-feeding their children；
(3) there are allergies, or allergic constitution person to Loratadine；
(4) it is associated with the severe primary disease patient such as angiocarpy, liver, kidney or hemopoietic system；
(5) psychiatric patient.
4th, treatment method
Treatment group：Tablet prepared by medicine (embodiment 2) of the present invention, 1.5 grams every time, 2 times a day, 30 days 1 courses for the treatment of；
Control group：Loratadine, each 10mg, one time a day, 30 days 1 courses for the treatment of.
5th, observation index and curative effect determinate standard
Observation index：
Clinical indices：Day by day clinical symptoms, sign change are observed during test, and monitors sending out for various bad reactions closely Raw time, performance, degree, process and result.
Lab index：Blood, urine, feces routine, Liver and kidney function are checked before test and after being discontinued.
Curative effect evaluation is classified：
Level Four is divided into according to clinical symptoms, the overall improvement degree of sign：
Recovery from illness：Clinical symptoms, sign recover normal；
It is effective：The state of an illness is clearly better, but not yet recovers completely normal；
Improve：The state of an illness take a favorable turn, but not obvious enough；
It is invalid：The state of an illness is without improvement or adds severe one.
6th, treatment results
After treatment group and control group treat respectively 30 days, clinical efficacy statistics is referring to table 2 below.Can from table 2 Go out, using drug therapy red blood silk of the present invention, wherein recovery from illness case load, effective case load and total effective rate are significantly larger than comparison medicine Loratadine, so as to prove can be than more preferably being controlled curative effect using drug therapy red blood silk of the present invention using Loratadine Really, and it is taken security and there has also been significant raising.
The treatment group of table 2 and treatment of control group curative effect comparision table after 30 days
Group Number of cases Recovery from illness It is effective Improve It is invalid Total effective rate
Treatment group 15 2 6 5 2 86.7%
Control group 15 0 2 5 8 46.7%
Model case
Female 21 years old, red blood trace on face is linked to be sheet, has a strong impact on face appearance, and patient once took multi-medicament and do not obtain Satisfied therapeutic effect.After medicine of the present invention has been taken 1 month, face red spot color and luster substantially shoals patient, continues to take medicine 1 Month, erythema disappears substantially, and follow-up 6 months after drug withdrawal, erythema does not occur again, it was demonstrated that medicine of the present invention has good to red blood silk Therapeutic action.
The preferred embodiments of the disclosure and embodiment are explained in detail above, but the present invention is not limited to The above-described embodiment and examples, in the ken that those skilled in the art possess, can be with without departing from the present invention Various changes can be made on the premise of design.

Claims (6)

1. a kind of medicine for treating red blood silk, it is characterised in that it is by made by the raw material of following weight proportioning：
2. the medicine of red blood silk is treated as claimed in claim 1, wherein the weight proportion of each raw material is：
3. the medicine of red blood silk is treated as claimed in claim 1, wherein the weight proportion of each raw material is：
4. the medicine of red blood silk is treated as claimed in claim 1, wherein the weight proportion of each raw material is：
5. the medicine of the treatment red blood silk as described in any one of claim 1-4, it is characterised in that the medicine is capsule, piece Agent or granule.
6. the preparation method of the medicine of red blood silk is treated described in claim 5, it is characterised in that comprised the following steps：
1) by Echinacea purpurea, cymose buckwheat rhizome, spina date seed, rosy clouds grass, lily, gardenia, Momordica grosvenori, Kadsura Root-bark, radix cynanchi atrati, oriental wormwood, rose, Dicliptera chinensis, catchweed bedstraw herb, balloonflower root, the root bark of tree peony, fimbriatestipulate begonia herb, cogongrass rhizome, climbing groundsel, frankincense, Poria cocos, globe amaranth, sanchi flower, Sweet Broomwort Herb, Add 8-12 times to measure water after the mixing of Ligusticum wallichii, Radix Glycyrrhizae, amaranth and FOLIUM HIBISCI MUTABILIS medicinal material, water rinsing, dry, crushing, soak 1 hour Afterwards, 1-3 hours are decocted, liquid filtration, filtrate is standby, repeats the dregs of a decoction to decoct 2-3 time under the same conditions, merging filtrate subtracts Pressure is concentrated into after small size and obtains mixing medicinal substances extract concentrate, is spray-dried to mixing medicinal substances extract concentrate, Obtain spray dried powder standby；
2) to take and carry out meal after the rinsing of pseudo-ginseng water, drying, the coarse powder particles of gained are put into into micronizer carries out ultra micro Crush, gained ultra-micro powder crosses that to obtain superfine notoginseng powder after 100-500 mesh sieves standby；
3) spray dried powder obtained in above steps and superfine notoginseng powder are mixed, is fully mixed in mixer, after granulation 8-20 mesh sieves are crossed, is dried, with 8-20 mesh sieve whole grains, capsule is filled after sterilization, packed, obtain final product this medicine capsule；
The preparation method of this medicinal tablet and granule is：Step with it is above-mentioned 1), 2) step, the 3) step by the conventional preparation in this area The method of tablet and granule is carried out, and this medicinal tablet and granule is obtained.
CN201610990523.4A 2016-11-10 2016-11-10 Medicine for treating couperose skin and preparation method of medicine Withdrawn CN106563089A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610990523.4A CN106563089A (en) 2016-11-10 2016-11-10 Medicine for treating couperose skin and preparation method of medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610990523.4A CN106563089A (en) 2016-11-10 2016-11-10 Medicine for treating couperose skin and preparation method of medicine

Publications (1)

Publication Number Publication Date
CN106563089A true CN106563089A (en) 2017-04-19

Family

ID=58541089

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610990523.4A Withdrawn CN106563089A (en) 2016-11-10 2016-11-10 Medicine for treating couperose skin and preparation method of medicine

Country Status (1)

Country Link
CN (1) CN106563089A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1546077A (en) * 2003-12-05 2004-11-17 玲 王 Blood streak removing medicine
CN101107998A (en) * 2007-09-06 2008-01-23 北京华昱安然医药科技有限公司 Health-care food improving memorization and method of preparing the same
CN105343542A (en) * 2015-11-30 2016-02-24 卞燕 Traditional Chinese medicine nursing composition for removing skin red blood

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1546077A (en) * 2003-12-05 2004-11-17 玲 王 Blood streak removing medicine
CN101107998A (en) * 2007-09-06 2008-01-23 北京华昱安然医药科技有限公司 Health-care food improving memorization and method of preparing the same
CN105343542A (en) * 2015-11-30 2016-02-24 卞燕 Traditional Chinese medicine nursing composition for removing skin red blood

Similar Documents

Publication Publication Date Title
CN101810800A (en) Chinese medicinal composition for treating skin itch and preparation method thereof
CN104027529A (en) Traditional Chinese medicine composition for regulating blood lipids, blood pressure and blood glucose and preparation method thereof
CN102178853B (en) Chinese medicinal preparation for treating infantile epilepsia and preparation method thereof
CN102406698B (en) External medicinal liquid for treating vitiligo
CN101961366A (en) Preparation method of malan straw extract, malan straw product, pharmaceutical composition and application thereof
CN104474341A (en) Pharmaceutical composition for treating attention deficit hyperactivity disorders
CN101810787A (en) Chinese medicinal composition for treating dysphoria and preparation method thereof
KR20110128384A (en) The composition material and the manufacturing process for skin-wrinkle, moisture and skin-lightening uses by midam-kyungokko
WO2023125797A1 (en) Traditional chinese medicine composition and preparation method and application thereof
CN104547523A (en) Medicine for enhancing immunity and preparation method thereof
CN105125708B (en) A kind of pharmaceutical composition and preparation method thereof for rhinitis
CN106563089A (en) Medicine for treating couperose skin and preparation method of medicine
CN102793870A (en) Chinese herbal medicine for treating renal calculi
CN102908396A (en) Chinese medicinal composition for promoting sleeping and preparation method thereof
CN105726921A (en) Traditional Chinese medicine composition and preparation for treating deficiency of both qi and blood
CN106728819A (en) A kind of medicine and preparation method for treating chronic dermatitis
CN109481602A (en) A kind of Chinese medicine composition and preparation method thereof of effective treatment acne
CN109288906A (en) A kind of relax bowel and defecation, nti-freckle Chinese medicine composition
JP6725955B1 (en) Zhuang pharmaceutical composition for blood supplementation and method for preparing the same
CN107308305A (en) It is a kind of to be used for infant eczema, dermatitis, the preparation of infantile eczema
CN106668240A (en) Pharmaceutical composition for treating vitreous opacity
CN106177461A (en) A kind of Chinese medicine and western medicine compound preparation treating neurasthenic syndrome and preparation method
CN106563068A (en) Medicine for treating corticosteroid-dependent dermatitis and preparation method of medicine
CN103784633B (en) A kind of Chinese medicine composition treating infantile rhinitis and preparation method thereof
CN104784475A (en) Traditional Chinese medicine formula extract for whitening skin and removing freckles and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20170419